Fresh attention to an inverted bacterial defence mechanism shows how basic science can create platform ideas, while the …
Fresh attention to an inverted bacterial defence mechanism shows how basic science can create platform ideas, while the …
A pivotal efficacy study and a separate G-CSF reduction trial could answer different questions, but market projections remain …
Three portfolio companies have entered first-in-human trials in oncology and anticoagulation, but the venture-biotech model will be judged …
The August 11 operating report puts clinic growth, NeuroStar utilisation and cost discipline at the centre of the …
The company is cutting operating costs while preserving investment in casdozokitug and tagmokitug, with mature clinical updates expected …
An August 5 public meeting convened by the Reagan-Udall Foundation for the FDA examined how approved medicines could …
Health Canada authorized the Phase 1 study of mRNA-1469 as an active outbreak in the Democratic Republic of …
Same-day announcements from Harbour BioMed and Ascletis show Chinese developers pairing discovery platforms with manufacturing scale, regulatory strategy, …
A Delaware jury awarded Yale and Biohaven $4 million after finding that Avilar Therapeutics and RA Capital willfully …
Starting July 31, large drugmakers face a 100 percent duty on patented medicines and active ingredients unless they …
Already a subscriber? Log in